148 related articles for article (PubMed ID: 21831744)
1. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
Cortes J; Quintas-Cardama A; Jabbour E; O'Brien S; Verstovsek S; Borthakur G; Ravandi F; Garcia-Manero G; Burton E; Shan J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):421-6. PubMed ID: 21831744
[TBL] [Abstract][Full Text] [Related]
2. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
Crisan AM; Coriu D; Arion C; Colita A; Jardan C
J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
[TBL] [Abstract][Full Text] [Related]
3. Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.
Bourlon C; Hernandez-Mata C; Vargas-Serafín C; Bourlon MT; Tuna-Aguilar E; Aguayo A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):453-9. PubMed ID: 27259590
[TBL] [Abstract][Full Text] [Related]
4. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Jabbour E; Kantarjian H; O'Brien S; Shan J; Quintas-Cardama A; Faderl S; Garcia-Manero G; Ravandi F; Rios MB; Cortes J
Blood; 2011 Oct; 118(17):4541-6; quiz 4759. PubMed ID: 21803854
[TBL] [Abstract][Full Text] [Related]
5. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Garg RJ; Kantarjian H; O'Brien S; Quintás-Cardama A; Faderl S; Estrov Z; Cortes J
Blood; 2009 Nov; 114(20):4361-8. PubMed ID: 19729517
[TBL] [Abstract][Full Text] [Related]
6. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Jabbour E; Kantarjian HM; O'Brien S; Shan J; Quintás-Cardama A; Garcia-Manero G; Rios MB; Cortes JE
J Clin Oncol; 2011 Nov; 29(32):4260-5. PubMed ID: 21990394
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.
Chitanava T; Matvienko I; Shuvaev V; Voloshin S; Martynkevich I; Vlasova Y; Efremova E; Mileeva E; Pirkhalo A; Makarova T; Vlasik R; Karyagina E; Il Ina N; Medvedeva N; Dorofeeva N; Shneider T; Siordiya N; Kulemina O; Sbityakova E; Lazorko N; Alexeeva J; Motorin D; Morozova E; Lomaia E
Front Oncol; 2023; 13():1138683. PubMed ID: 37007128
[TBL] [Abstract][Full Text] [Related]
8. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
Jabbour E; Kantarjian H; Ghanem H; O'Brien S; Quintas-Cardama A; Garcia-Manero G; Cardenas M; Cortes J
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):302-6. PubMed ID: 23318257
[TBL] [Abstract][Full Text] [Related]
9. Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
DeAngelo DJ; Chen L; Guerin A; Styles A; Giguere-Duval P; Wu EQ
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):245-51. PubMed ID: 24393622
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
12. Practical monitoring of chronic myelogenous leukemia: when to change treatment.
Saglio G; Fava C
J Natl Compr Canc Netw; 2012 Jan; 10(1):121-9. PubMed ID: 22223872
[TBL] [Abstract][Full Text] [Related]
13. [Clinical Efficacy of Second-generation Tyrosine Kinase Inhibitor in Treating Chronic Myeloid Leukemia].
Lyu SJ; Zhu HL; Li XL; Ren WR; Zheng SP; Wu Y; Niu T; Liu T
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Mar; 47(2):287-91. PubMed ID: 27263312
[TBL] [Abstract][Full Text] [Related]
14. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Fava C; Kantarjian HM; Jabbour E; O'Brien S; Jain N; Rios MB; Garcia-Manero G; Ravandi F; Verstovsek S; Borthakur G; Shan J; Cortes J
Blood; 2009 May; 113(21):5058-63. PubMed ID: 19282457
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Quintás-Cardama A; Cortes JE; O'Brien S; Ravandi F; Borthakur G; Liu D; Bleickardt E; Chen TT; Kantarjian HM
Cancer; 2009 Jul; 115(13):2912-21. PubMed ID: 19402171
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
Lai Y; Qin Y; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
[TBL] [Abstract][Full Text] [Related]
17. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
Quintás-Cardama A; Kantarjian H; Jones D; Shan J; Borthakur G; Thomas D; Kornblau S; O'Brien S; Cortes J
Blood; 2009 Jun; 113(25):6315-21. PubMed ID: 19369233
[TBL] [Abstract][Full Text] [Related]
18. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
Falchi L; Kantarjian HM; Wang X; Verma D; Quintás-Cardama A; O'Brien S; Jabbour EJ; Ravandi-Kashani F; Borthakur G; Garcia-Manero G; Verstovsek S; Burger JA; Luthra R; Cortes JE
Am J Hematol; 2013 Dec; 88(12):1024-9. PubMed ID: 23913852
[TBL] [Abstract][Full Text] [Related]
19. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Ravandi F; Jabbour E; Shan J; Cortes J
Cancer; 2012 Jun; 118(12):3116-22. PubMed ID: 22370904
[TBL] [Abstract][Full Text] [Related]
20. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]